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LETTERS TO THE EDITOR
EBUS-TBNA for the
Mediastinal Staging of
Non-small Cell Lung
Cancer
To the Editor:
The mediastinal staging of non-
small cell lung cancer is an important
process that distinguishes operable from
inoperable candidates. In their retrospec-
tive study, Rintoul et al.1 report the util-
ity of endobronchial ultrasound guided
transbronchial needle aspiration (EBUS-
TBNA) for the diagnosis of positron
emission tomography (PET) positive
mediastinal and hilar lymph nodes. They
demonstrate a sensitivity of EBUS-
TBNA of 91% when reference pathol-
ogy was available.
The high false-positive rate of
PET for the detection of mediastinal
metastases demands that PET-positive
mediastinal nodes should be inva-
sively sampled and proven to contain
metastatic disease before radical treat-
ment is precluded. However, in addi-
tion to a high false-positive rate, it is
increasingly recognized that PET is
associated with a significant false-neg-
ative rate. The pooled sensitivity of
PET for detecting mediastinal metas-
tases from a meta-analysis was 0.74
(95% CI 0.69–0.79) and therefore
PET scanning fails to detect over a
quarter of mediastinal metastases in
non-small cell lung cancer.2 This is
reflected by current guidelines which
suggest that all mediastinal lymph
nodes 1 cm should be sampled pre-
operatively, regardless of fluorode-
oxyglucose-avidity.3 Emerging data
also suggests that malignancy can be
detected in PET negative mediastinal
nodes that are less than 1 cm in short
axis.4 Therefore, a strategy where PET
positive mediastinal lymph nodes alone
are sampled should not be advocated.
The value of PET lies in its ability
to detect radiographically occult ex-
trathoracic metastases5 and should be
applied preoperatively in all cases.
However, EBUS-TBNA has a higher
sensitivity for the detection of mediasti-
nal metastases than PET. Therefore re-
stricting the application of EBUS-
TBNA to only PET positive mediastinal
nodes would miss mediastinal metasta-
ses preoperatively and result in futile
thoracotomies.
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In Response:
We thank Navani and colleagues
for their letter in response to our recent
article published in the Journal of Tho-
racic Oncology.1 As they indicate, our
article addressed the issue about the ne-
cessity of sampling positron emission
tomography (PET) positive mediastinal
lymph nodes before a treatment decision
to confirm or refute that they contain
malignancy. We described the test char-
acteristics of curved-linear endobron-
chial ultrasound with transbronchial
needle aspiration in this particular set-
ting. However, the letter from Navani
and colleagues addresses a very differ-
ent issue. They are asking whether PET
negative lymph nodes greater than 1 cm
in short axis dimension should also be
sampled given recent data indicating
that PET has a significant false-negative
rate for detection of metastatic disease in
mediastinal nodes.2 This is an interest-
ing and topical question which we did
not address in our article.
Currently, the latest American
College of Chest Physicians guidelines
(2007) suggest that all enlarged (10
mm short axis) mediastinal lymph nodes
should be biopsied regardless of Fluoro-
deoxyglucose (FDG) avidity. The Euro-
pean Society of Thoracic Surgeons
guidelines use a cutoff of 16 mm.3 This
is based on a meta-analysis of 14 stud-
ies, which examined the posttest proba-
bility of N2 disease in patients with
enlarged but PET negative nodes.4 In
nodes measuring 10 to 15 mm, N2 dis-
ease was present in 5% of patients
whereas in nodes measuring 16 mm
the prevalence was 21%. In addition,
both guidelines recommend sampling of
FDG negative mediastinal lymph nodes
if there is either a central tumor or FDG
positive N1 nodes are present. Although
it is recognized that no amount of me-
diastinal staging will exclude all mi-
crometastatic disease in every patient
a balance needs to be struck between
maximizing the chance of detecting oc-
cult N2 disease preoperatively while not
subjecting patients to too many tests.
Further work in this area is needed.
The current authors are presently
completing recruitment to the Assess-
ment of Surgical sTaging versus En-
doscopic ultrasound in lung cancer: a
Randomised controlled trial, a large
international randomized controlled
trial of endobronchial and endoscopic
ultrasound guided mediastinal staging
versus surgical staging for patients
who require mediastinal staging before
surgical resection.5 The entry criteria
include both those with computed to-
mography-PET positive lymph nodes
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